APTO

Aptose Biosciences

3.69 USD
-0.09
2.38%
At close Mar 14, 4:00 PM EDT
1 day
-2.38%
5 days
18.27%
1 month
-31.67%
3 months
-35.04%
6 months
-66.67%
Year to date
-47.81%
1 year
-91.21%
5 years
-99.83%
10 years
-99.86%
 

About: Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Employees: 36

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 26 [Q3] → 26 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

11.14% less ownership

Funds ownership: 17.84% [Q3] → 6.7% (-11.14%) [Q4]

32% less capital invested

Capital invested by funds: $1.33M [Q3] → $897K (-$431K) [Q4]

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$60
1,526%
upside
Avg. target
$60
1,526%
upside
High target
$60
1,526%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
18% 1-year accuracy
73 / 408 met price target
1,526%upside
$60
Buy
Reiterated
12 Feb 2025

Financial journalist opinion

Based on 3 articles about APTO published over the past 30 days

Positive
Benzinga
3 weeks ago
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
On Thursday, Aptose Biosciences Inc. APTO announced that the Cohort Safety Review Committee monitoring Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 40 mg TUS to 80 mg TUS based on its favorable review of data from the first four patients in the trial.
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
Neutral
GlobeNewsWire
3 weeks ago
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Neutral
GlobeNewsWire
3 weeks ago
Aptose Announces Reverse Share Split
SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that its board of directors (the “Board”) has approved, subject to required regulatory and stock exchange approvals, a plan to consolidate all of its outstanding common shares (the “Common Shares”) on the basis of 1 Common Share for every 30 Common Shares currently outstanding (the "Reverse Share Split"). The Company expects the Reverse Share Split to restore compliance with the minimum bid price requirement set out in Nasdaq Listing Rule 5550(a)(2) and to ensure the Company continues to have access to a wide range of investors.
Aptose Announces Reverse Share Split
Neutral
GlobeNewsWire
1 month ago
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced it has entered into a common share purchase agreement and registration rights agreement with an institutional investor. The Committed Equity Facility agreement provides Aptose the right, in its sole option and discretion without obligation, to sell and issue up to $25 million of its common shares (the “Common Shares”) over the course of 24 months to the Investor, subject to certain conditions being met, and subject to certain limitations and conditions imposed by the Nasdaq Capital Market (“Nasdaq”), the U.S. Securities and Exchange Commission (the “SEC”) and other regulators.
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
Neutral
GlobeNewsWire
1 month ago
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML TUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patients TUS+VEN+AZA triplet shows favorable safety with no alteration of VEN and AZA dosing PK levels of TUS in the triplet remain equivalent to levels as TUS or TUS+VEN therapy SAN DIEGO and TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose's Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet). The TUS+VEN+AZA triplet is being developed as a frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy.
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
Neutral
GlobeNewsWire
2 months ago
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline triple drug combination (triplet) therapy for patients newly diagnosed with acute myeloid leukemia, or AML. Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated.
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Neutral
GlobeNewsWire
2 months ago
Aptose Announces Positive Decision by Nasdaq Hearings Panel
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that the Nasdaq Hearings Panel (“Panel”) has granted the Company's request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Stock Market. On or before March 31, 2025, the Company will be required to demonstrate compliance with NASDAQ Listing Rule 5550(b)(1) requiring the Company to have a minimum of $2.5 million in shareholders' equity (the “Equity Rule”) and NASDAQ Listing Rule 5550(a)(2) requiring the Company to have a minimum bid price of $1.00 (the “Minimum Bid Price Rule”).
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Neutral
GlobeNewsWire
3 months ago
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
Neutral
GlobeNewsWire
3 months ago
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. Sites TUS and TUS+VEN Broadly Active Across AML Populations, with Favorable Safety TUS-based therapies are active in FLT3 wildtype, representing ~70% of AML patients TUS Targets VEN Resistance Mechanisms, Enabling TUS+VEN to Achieve Responses in Difficult-to-treat Prior-VEN Failure AML SAN DIEGO and TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today featured a wealth of clinical data for Aptose's lead compound tuspetinib (TUS) in a poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. Poster title: “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML” Key Findings and Messages: TUS+VEN+AZA triplet trial is proceeding in newly diagnosed AML patients TUS+VEN retains activity in the difficult-to-treat prior-VEN AML population TUS+VEN is active in FLT3 wildtype, representing ~70% of AML patients TUS+VEN is well tolerated and can be safely co-administered TUS+VEN is active across broad populations of R/R AML Combination of TUS with VEN may avoid VEN resistance TUS+VEN+AZA triplet may establish a more effective, mutation agnostic standard of care for chemotherapy ineligible AML patients Tuspetinib (TUS), being developed by Aptose and originally created by Hanmi Pharmaceutical Co., is being advanced as the TUS+VEN+AZA triplet (tuspetinib+venetoclax+azacitidine) for frontline therapy of newly diagnosed AML patients ineligible for intensive chemotherapy.
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Neutral
GlobeNewsWire
3 months ago
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Charts implemented using Lightweight Charts™